The main risks arising from the WTO Agreement are the inequality and lack of competitiveness
of most pharmaceutical goods, as well as the fact that Iraq is a net importer of medicines that are
at the core of consumer needs, The subject matter of the Convention on the Protection of
Intellectual Property Rights and its implications for the pharmaceutical industry, in particular,
coinciding with the situation of financial and administrative corruption, all of which has resulted
in drug fraud in the Iraqi market and its impact on public health. The control of medical
technology, the persistence of the technological gap and its effects on high price levels, and the
fact that domestic drug producers are obliged to obtain production licenses from global companies
in the light of limited access to pharmaceutical research and development. The research aims at
the impact of economic liberalization within the World Trade Organization (WTO) and its
negative effects on consumers by highlighting the economic and social effects on consumption by
raising prices and monopolies and restricting the volume of consumer demand because of the loss
of the competitive advantage of pharmaceutical goods. Iraq's unwillingness to accede to the
International Convention for the Protection of Intellectual Property Rights of the World Trade
Organization (WTO) and the deterioration of the pharmaceutical industry meant increased
dependence on the outside, increased trade deficits, higher price levels, and its adverse effects on
consumers. Iraq finds it difficult for developed countries to use their intellectual rights as well as
restrict industrial and agricultural work because production and production methods are now
subject to their intellectual property protection law, which prevents any possible industrial
development. The most significant potential short-term impact of TRIPS is the decline in drug
production, which continues to be protected. The great challenge for drug producers is the need to
Intellectual property rights and its implications for the pharmaceutical industry in Iraq under accession to the World Trade Organization
